Making evidence-based peptide protocols accessible
The gap
Most people interested in peptides face a binary choice: trust anonymous forum advice or find a specialised physician who may not exist in their country. The first option risks your health on protocols written by users with no clinical context, no liability, and no idea what your bloodwork looks like. The second option costs thousands per consult, has a months-long waitlist in most cities, and is unavailable entirely in the jurisdictions where peptide-curious adults actually live. There has not been a middle ground that takes the methodology of a specialised consult and makes it accessible, reproducible, and reviewable. Klarovel is the attempt to build that middle ground.
Our approach
Klarovel encodes the evidence-based methodology of peptide therapy into a deterministic rules engine. The same logic a specialised longevity clinician uses to evaluate a health profile, screen contraindications, select appropriate peptides, calibrate doses, and design a cycling schedule, applied systematically to every user. No shortcuts, no probabilistic guesswork, no generic templates that ignore the user in front of you. The engine output is then translated into a readable report by an AI layer that is explicitly not allowed to invent doses, override contraindications, or change a recommendation the engine made. The result is a protocol you can read, question, and bring to a clinician for sign-off, with every decision traceable back to a rule.
Who Klarovel is for
Klarovel is built for adults who want their peptide protocol grounded in their own health data, not in a generic dosing template they found on a forum. Four reader profiles show up most often:
The longevity-curious adult who is already tracking biomarkers and wants a protocol calibrated against IGF-1, HbA1c, lipid panel, hormone screen, not against body weight alone.
The athlete or recovery-focused user evaluating BPC-157, TB-500, or GHK-Cu against a real injury or training-load context, with stacking rules and cycle length pinned to research-published protocols.
The weight-management adult considering GLP-1 class options (semaglutide, tirzepatide, retatrutide) and the GLP-1-adjacent compounds, looking for titration math and a side-effect plan rather than marketing.
The clinician or peptide-curious professional who wants to see what a deterministic, biomarker-aware protocol engine produces, and to evaluate its outputs against their own clinical framework.
If you do not see yourself in those profiles, the questionnaire is still the right starting point. The engine adapts to the data you actually have, including the case where bloodwork is not yet available, and the protocol will surface what additional information would sharpen the next cycle.
What we believe
Peptide protocols should be personalised to the individual, not copied from forums. A protocol is a downstream consequence of someone's goals, biomarkers, contraindications, and experience tier; the moment that link is broken, the protocol becomes a marketing template.
Safety must be evaluated before any recommendation is made. Contraindication screening runs first in the pipeline because no efficacy gain justifies a downstream cardiovascular or oncologic risk that the engine could have caught upfront.
Dosing should be calibrated to biomarkers, age, sex, and experience tier, not to body weight alone. The IGF-1 SDS score, HbA1c, fasting insulin, and renal function all move the dose envelope; ignoring them produces a protocol calibrated for a population average that may not match the individual.
Every protocol needs a documented lifecycle: titration, full dose, monitoring checkpoints, off-cycle, follow-up assessment, renewal. Without the lifecycle the protocol is a one-shot recommendation, and one-shot recommendations are the failure mode that produced this whole problem.
The science should be accessible to anyone willing to invest in their health, not gated behind a clinic that may not exist in their country or behind a forum culture that treats clinical caution as weakness. Accessibility does not mean watering down the evidence; it means showing the work.
What we are not
Klarovel does not sell or distribute peptides, directly or through anyone else. We do not hold inventory, run a pharmacy, or take medical custody of any product, and we earn nothing when you buy a compound somewhere. We do not provide medical advice, diagnose, or treat any condition; the protocol is a structured document, not a clinical decision. Where you live may regulate the importation, possession, or use of specific peptides; the engine surfaces the regulatory framing where it touches your jurisdiction, but you are responsible for compliance. We are the protocol intelligence layer. We help you design a protocol grounded in your data, and we make every engine decision traceable so a clinician can review it. Acting on it, and sourcing anything you decide to take, is yours alone. Your decisions are your own. We provide the intelligence to make them well.
How we publish
Every long-form post on Klarovel is built against a documented editorial standard that exists precisely because most consumer-facing peptide content is unsafe to trust.
Every load-bearing claim carries an inline link to a primary source: peer-reviewed literature, regulator publications, recognised guideline bodies, or authoritative reference works. Forums, Wikipedia, Substack, YouTube, and X threads are not cited as evidence.
Dose statements are verified against the published peptide research catalogue and the engine's research-ceiling table. If the literature does not support a dose, the post does not publish it, regardless of how common the forum recommendation is.
Where the literature is genuinely thin or split, we hedge in the prose and name the gap explicitly. The editorial failure mode we treat as a critical error is pretending to have answers the field does not have.
Every post carries a documented medical review date that the Klarovel Medical Advisory Board updates only when a load-bearing claim moves: a new study citation, a regulatory fact change, a dose-statement change, a contraindication change. Cosmetic edits do not bump the date because the date is a clinical vouching signal, not a last-touched timestamp.
What Klarovel is, and is not
Klarovel does not sell peptides. Not directly, and not through third parties. There is no shop, no cart, no order flow, and no commission on anything you buy anywhere. The platform generates a protocol from your data and stops there. Where you obtain a compound, and from whom, is entirely your own arrangement, and Klarovel earns nothing from it either way. The product is the protocol layer: the questionnaire, the deterministic engine, the dosing and cycling and monitoring rules, and the reasoning behind each recommendation. It is funded by the protocol itself, which is the only thing Klarovel charges for. That separation is not a marketing line, it is the operational shape of the platform, and it is set out in full on the disclosures page rather than buried in a footer footnote.